Stocklytics score rationale: value 66, quality 60, growth 54.
Financials
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
1487973000
1618693000
1890922000
2161761000
2363567000
3094238000
3659374000
3834204000
4068950000
4267586000
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the…
Forecast
Consensus Buy from 22 analysts. Average price target $292.27, +39.4% versus the current price. Low $229.00. High $337.00.
Analysts have an average 12-month price target of $292.27 for Jazz Pharmaceuticals (JAZZ), 41.3% above the current price of $206.91. Of 22 analysts covering the stock, 20 rate it Buy or Strong Buy, 2 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
JAZZ price target
12-month price target
Low
$229.00
Average
$292.27
High
$337.00
The average is 41.3% above the current price of $206.91.
Is Jazz Pharmaceuticals a buy or sell?
Of 22 analysts, 20 rate Jazz Pharmaceuticals Buy or Strong Buy, 2 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
Jazz Pharmaceuticals earnings and revenue forecast
The Stocklytics Score for JAZZ is 60 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
JAZZ forecast FAQs
What is the JAZZ price target?
$292.27 average, with a published range of $229.00 to $337.00.
Is Jazz Pharmaceuticals a buy or sell?
The consensus is Buy from 22 analysts. This is not a recommendation.
What is the Jazz Pharmaceuticals stock forecast for 2026?
Analysts' average EPS estimate for 2026 on file is $24.58. The average revenue estimate is $4.73 billion.
What will JAZZ be worth in 2030?
No reliable forecast exists that far out.
When is Jazz Pharmaceuticals's next earnings report?
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.